A5072416174- Myasthenia Gravis and Thymoma
- Peripheral Neuropathies and Disorders
- Autoimmune Neurological Disorders and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Pituitary Gland Disorders and Treatments
- Cancer Treatment and Pharmacology
- Neuroblastoma Research and Treatments
- Retinal and Optic Conditions
- Vasculitis and related conditions
- Antifungal resistance and susceptibility
- Parkinson's Disease and Spinal Disorders
- Cellular transport and secretion
Università Cattolica del Sacro Cuore
2022-2025
Agostino Gemelli University Polyclinic
2023-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2025
German Center for Neurodegenerative Diseases
2024
University of Oxford
2024
University of Florence
2024
Light sensitivity is occasionally reported in myasthenia gravis patients, yet its prevalence, clinical characteristics, and impact on disease severity quality of life remain insufficiently explored. This study aimed to evaluate the frequency, correlation light with patients. Myasthenia patients consecutively admitted Fondazione Policlinico Universitario A. Gemelli Rome between March October 2023 were considered for study. A demographically matched group healthy controls was also included....
Cancer frequency in muscle‐specific kinase myasthenia gravis (MuSK‐MG) has not yet been explored and the mechanisms leading to formation of MuSK IgG remain elusive. We aimed explore cancer MuSK‐MG patients assess expression cells from 2 tumors occurred this cohort. Immunohistochemistry on tumor specimens revealed primary mediastinal B cell lymphoma endometrial carcinoma. Twenty‐one males 73 females were enrolled. Fifteen cancers 13 94 (13.8%). Patients with significantly older at time onset....
Acetylcholine receptor antibody (AChR-Ab) detection is crucial in myasthenia gravis (MG) diagnosis and, currently, the radioimmunoassay (RIA) gold standard. However, RIA may detect AChR-Ab against nonpathogenic intracellular epitopes. In this study, we performed fixed cell-based assay (F-CBA) RIA-AChR-Ab positive subjects without MG symptoms, to assess whether F-CBA could show a higher specificity compared detecting pathogenic Abs.
Abstract To increase the neurological results in patients older than 65 years with myasthenia gravis after thymectomy, we retrospectively analysed this outcome a large bicentric cohort of (MG)years, for which surgery was indicated concurrent thymoma. From 1/2000 to 2/2022, 502 underwent thymectomy thymic epithelial tumours (TETs) two high-volume Institutions (167aged more years). Among them, 66 were affected by TET and MG, representing our final study group. The mean age MG onset 68.3 ± 6...
In this retrospective longitudinal study, we aimed at exploring the role of (a) MuSK-immunoglobulin G (IgG) levels, (b) predominant MuSK-IgG subclasses, and (c) antibody affinity as candidate biomarkers severity outcomes in MuSK-MG, using comparing different testing techniques.